Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in relapsing neuromyelitis optica (NMO)
NCT01892345Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Participants With An Adjudicated On-trial Relapse at 211 weeks. Started Apr 2014; status: terminated.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT01892345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892345.